The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
By Stephen J. Ubl | January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...
Read More
PhRMA CEO Statement Following Meeting With President Trump
By Stephen J. Ubl | January 31, 2017
This morning, we had a positive, productive meeting with President Trump, Vice President Pence and House Energy and Commerce Chairman Greg Walden, (R-Ore.). We talked about how we can work...
Read More
Medicare Monday: How Part D helps patients with heart disease live longer, healthier lives
By Nicole Longo | January 30, 2017
Wednesday kicks off American Heart Month, so this week we’re looking at heart health and how important it is for patients to have access to needed medicines for heart disease and stroke. This is...
Read More
Ask About Adherence: Q&A on appointment-based medication synchronization
By Samantha Dougherty | January 27, 2017
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we spoke with David A. Holdford, Ph.D., Professor, Director of...
Read More
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
By Holly Campbell | January 24, 2017
PhRMA President and CEO Stephen J. Ubl spoke with the anchors of CNBC’s Squawk on the Street about the biopharmaceutical industry’s new national, multi-year advertising and public affairs...
Read More
Medicare Monday: How Medicare helps beneficiaries access needed medicines
By Nicole Longo | January 23, 2017
Throughout 2016, we looked at how different groups of beneficiaries – from seniors to minority communities to individuals with lower-incomes – rely on Medicare to access their needed prescription...
Read More
Medicare Monday: A closer look at Medicare Part B
By Kelsey Lang | January 16, 2017
We took a deeper dive on Medicare Part D last week, so today we’re switching gears and talking about Medicare Part B.
Read More
The 20-year journey yielding a new weapon against cancer
By Andrew Powaleny | January 10, 2017
Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...
Read More
Significant progress fighting cancer: Death rate has dropped 25 percent
By Holly Campbell | January 9, 2017
Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, the cancer death rate...
Read More
Medicare Monday: A refresh on private negotiation in Part D
By Nicole Longo | January 9, 2017
Last week, we highlighted a number of Medicare resources – from how to learn more about which medicines are covered in Part B to how Part D has been a success since its implementation. And this...
Read More
3 things to know about 2016 drug approvals
By Andrew Powaleny | January 6, 2017
In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need. These...
Read More
Medicare Monday: Kicking off 2017 with Medicare resources
By Nicole Longo | January 2, 2017
Happy New Year, #MedicareMonday readers!
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
